Please login to the form below
MabThera
This page shows the latest MabThera news and features for those working in and with pharma, biotech and healthcare.
Roche and AbbVie prepare to move Venclexta into first-line CLL
Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for
Latest news
-
Roche’s new flu pill Xofluza approved in US
Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.
-
Ocrevus surge keeps Roche smiling in Q3
As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... Sales of immunology drug MabThera (rituximab) in the EU were almost cut in half in the first nine
-
Encouraging data for Roche flu drug ahead of FDA decision
Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.
-
ABPI hits out at ‘punitive’ UK medicines pricing plan
Herceptin, MabThera and Humira – but Warwick Smith says the new plan puts this target in jeopardy.
-
Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down
Roche has seen revenues from blockbuster MabThera/Rituxan slashed in half in Europe thanks to growing biosimilar competition in the second quarter.
More from news
Approximately 17 fully matching, plus 112 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and Herceptin.
-
Deal Watch November 2016
We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in
-
Pharma deals in June 2015
Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach. ... Herceptin SC and MabThera SC can be administered in approximately 5 minutes by sc injection
-
Russian innovation at the crossroads
For example, in autumn 2014, BIOCAD fully pushed out Roche's Mabthera (rituximab) from public procurement.
-
Pharma deals during December 2014
Subcutaneous formulations of both MabThera and Herceptin based on the Halozyme technology have been launched by Roche.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Sanofi hires David Loew from Roche
He gradually rose up the ranks at Roche, holding senior marketing positions such as life cycle leader for both MabThera and Xeloda, head of oncology and chief marketing officer, before taking
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
Biosimilars: Getting the flock to market
The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Manager / Account Director
-
Competative
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Competitive Salary
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Director
-
£75, 000-90, 000
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Account Director
-
£48, 000 - £60, 000
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
-
New Business Director - PR
-
Competitive Salary and benefits
Subscribe to our email news alerts
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
